+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Kinase"

From
From
Thymidine Kinase 2 Deficiency (TK2D) - Pipeline Insight, 2024 - Product Thumbnail Image

Thymidine Kinase 2 Deficiency (TK2D) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
From
Hematopoietic progenitor kinase 1 inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Hematopoietic progenitor kinase 1 inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Polo-Like Kinase 1 (PLK1) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Polo-Like Kinase 1 (PLK1) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Mayus Kinase 1 (JAK1) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Mayus Kinase 1 (JAK1) Inhibitor - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 90 Pages
  • Global
From
Fms-like tyrosine kinase 3 inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Fms-like tyrosine kinase 3 inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 70 Pages
  • Global
From
MAP kinase kinase 1 inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

MAP kinase kinase 1 inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Checkpoint Kinase 2 (Chk2) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Checkpoint Kinase 2 (Chk2) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Casein Kinase 2 Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Casein Kinase 2 Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Checkpoint Kinase 1 (Chk1) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Checkpoint Kinase 1 (Chk1) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Cyclin-Dependent Kinase 1 (CDK1) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Cyclin-Dependent Kinase 1 (CDK1) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Mayus Kinase 3 (JAK3) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Mayus Kinase 3 (JAK3) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
Cyclin-Dependent Kinase 2 (CDK2) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Cyclin-Dependent Kinase 2 (CDK2) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Loading Indicator

The Kinase market is a subset of the Drug Discovery market, focusing on the development of drugs that target kinases, a type of enzyme that plays a role in many cellular processes. Kinase inhibitors are used to treat a variety of diseases, including cancer, diabetes, and neurological disorders. Kinase inhibitors are typically small molecules that bind to the active site of the kinase, blocking its activity. Kinase inhibitors are developed through a combination of in vitro and in vivo assays, as well as computational modeling. Companies in the Kinase market are focused on developing novel inhibitors that can be used to treat a variety of diseases. These companies include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more